Most cancer patients show a low level of basal NK cell activity compared to healthy individuals. Thus, a decline in NK cell count and function appears to be a biomarker of overall cancer disease risk. When activated NK cells increase the release of granzyme, perforin and contribute to the killing of more cancer cells conjointly with chemotherapy. One of the advantages of RBAC is to sensitize various chemotherapeutic agents (and radiotherapy) to increase their effectiveness such as with Daunorubicin and Paclitaxel in metastatic breast cancer cells (12,13).
Figure 3: RBAC is Synergistic with Chemotherapy
Discussion
Natural killer cells are now viewed as a possible first line of defense against cancer to restrict the progression of carcinogenesis. A large number of rigorous preclinical and clinical research studies have shown that the basis of the anticancer effect of RBAC is founded on the ability of this natural compound to act as a potent Biological Response Modifier (BRM). RBAC has demonstrated its potential as an anticancer agent acting as a cancer treatment adjuvant working in synergy with chemotherapy by increasing its efficacy, reducing side effects, improving Quality of life, and increasing survival rate.
In metastasis cancer, late-stage III-IV in a study (96 patients) compared with control group (109 patients) treated during 18 months. The more NK cells activated, the more the rate of survival increased: 54% with the group of patients taking RBAC and 36% for the group without RBAC.